Author + information
Background: Multi-gated acquisition (MUGA) scans have been used for cardiac assessment in patients receiving cardiotoxic chemotherapy, however, echocardiography is preferred in some guidelines. We sought to describe the trends of cardiac function testing in patients undergoing chemotherapy, and association with use of cardioprotective therapies.
Methods: A large clinical registry (Explorys) was used to identify adults who were prescribed anthracyclines or trastuzumab between 2008 and 2015. We identified utilization of MUGA, echocardiograms, beta-blockers (BB) and angiotensin convertase enzyme inhibitors (ACE) or angiotensin-receptor blockers (ARB) during the year of chemotherapy.
Results: 20,440 patients were identified as receiving cardiotoxic chemotherapy, of whom 11,600 (57%) underwent echocardiography and 3770 (18%) underwent MUGA. Echocardiography rates increased from 48% (2008) to 61% (2015), p<0.001; while MUGA decreased from 25% (2008) to 15% (2015), p<0.001. Trends in echocardiography utilization correlated with BB (Spearman r=0.833, p=0.01) and ACE/ARB (r=0.881, p=0.004), while MUGA utilization negatively correlated with BB (r=-0.714, p=0.047) and ACE/ARB (r=-0.690, p=0.058).
Conclusions: These findings suggest that echocardiography has slowly replaced MUGA as the preferred method for cardiotoxicity evaluation. Echocardiography utilization was associated with higher use of cardioprotective medications possibly due to earlier detection of cardiotoxicity.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Emerging Applications of Echocardiography
Abstract Category: 28. Non Invasive Imaging: Echo
Presentation Number: 1160-223
- 2017 American College of Cardiology Foundation